Pluronic/Heparin Nanoparticles for Chemo-Photodynamic Combination Cancer Therapy through Photoinduced Caspase-3 Activation
Source abstract
Abstract
The Pluronic/heparin nanoparticles (NPs) were prepared for chemo-photodynamic combination cancer therapy through photoinduced caspase-3 activation. Doxorubicin (DOX) prodrug and methylene blue (MB) were assembled into a single structure by electrostatic interaction with heparin and further loaded into the NPs. MB is a photosensitizer, which can be used for photodynamic therapy, which can elicit cell death by producing reactive oxygen species (ROS). The DOX prodrug was DOX conjugated to a labile tetrapeptide (DEVD) by caspase-3 upon apoptosis. ROS was measured to verify ROS-mediated apoptosis. Membrane integrity test and flow cytometry analysis were performed to examine induced apoptosis. The tumor targeting and the in vivo antitumor efficacy were measured to evaluate chemo-photodynamic combination cancer therapy in tumor-bearing mice.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Angiogenesis and VEGF in Cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Pharmacy, Korea University, 2511 Sejongro, Sejong 30019, Republic of Korea
Biomedical Research Center, Korea University Guro Hospital, Guro-gu, Seoul 08308, Republic of Korea
Department of Otolaryngology, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea
TGel Bio Co., Ltd., 8 Samsungro, 86 gil,Gangnam-gu, Seoul 06185, Republic of Korea
Department of Biomedical Engineering, The University of Iowa, Iowa City, Iowa 52242, United States
Funding
Ministry of Health and Welfare · Ministry of Trade, Industry and Energy · Ministry of SMEs and Startups
References (50)
Show source-provided references
1. 10.1021/acsanm.7b0017610.1021/acsanm.7b00176 ↗
2. 10.1021/acsanm.7b0019610.1021/acsanm.7b00196 ↗
3. 10.1016/j.jconrel.2015.11.00710.1016/j.jconrel.2015.11.007 ↗
4. 10.1021/nn506963h10.1021/nn506963h ↗
5. 10.1016/j.jaad.2006.06.00610.1016/j.jaad.2006.06.006 ↗
6. Nestor M. S. · J. Drugs. Dermatol. · 2006 · 5 · 140
7. 10.1016/j.det.2006.09.00710.1016/j.det.2006.09.007 ↗
8. 10.1016/0190-9622(93)70002-B10.1016/0190-9622(93)70002-B ↗
9. 10.1038/bjc.1994.11210.1038/bjc.1994.112 ↗
10. 10.1016/j.jphotobiol.2010.07.00210.1016/j.jphotobiol.2010.07.002 ↗
11. 10.1016/j.gie.2005.07.01710.1016/j.gie.2005.07.017 ↗
12. 10.1046/j.1365-2133.2001.04141.x10.1046/j.1365-2133.2001.04141.x ↗
13. 10.1378/chest.81.3.26910.1378/chest.81.3.269 ↗
14. 10.1007/978-1-60761-697-9_1710.1007/978-1-60761-697-9_17 ↗
15. 10.1055/s-2007-101043310.1055/s-2007-1010433 ↗
16. 10.1002/lsm.190017010310.1002/lsm.1900170103 ↗
17. 10.1016/S0016-5085(98)70527-X10.1016/S0016-5085(98)70527-X ↗
18. 10.1111/j.1751-1097.1992.tb04222.x10.1111/j.1751-1097.1992.tb04222.x ↗
19. 10.1039/B507082A10.1039/B507082A ↗
20. 10.1089/pho.2006.24.52810.1089/pho.2006.24.528 ↗
21. 10.1111/j.1365-2230.2011.04291.x10.1111/j.1365-2230.2011.04291.x ↗
22. 10.1097/00000542-197610000-0002010.1097/00000542-197610000-00020 ↗
23. Buehring G. C. · Cancer Res. · 1983 · 43 · 6039
24. 10.1021/jm00166a00510.1021/jm00166a005 ↗
25. 10.1002/bjs.180062091910.1002/bjs.1800620919 ↗
26. 10.1016/S0022-5347(17)51088-510.1016/S0022-5347(17)51088-5 ↗
27. 10.1111/j.1751-1097.1991.tb08466.x10.1111/j.1751-1097.1991.tb08466.x ↗
28. 10.1016/1011-1344(93)80173-710.1016/1011-1344(93)80173-7 ↗
29. 10.1111/j.1349-7006.2008.00910.x10.1111/j.1349-7006.2008.00910.x ↗
30. 10.1056/NEJMp04811310.1056/NEJMp048113 ↗
31. 10.1038/sj.onc.120636610.1038/sj.onc.1206366 ↗
32. 10.1016/j.taap.2012.10.02510.1016/j.taap.2012.10.025 ↗
33. 10.1093/jnci/dju40310.1093/jnci/dju403 ↗
34. 10.1016/j.biomaterials.2016.05.05610.1016/j.biomaterials.2016.05.056 ↗
35. 10.1016/j.jconrel.2017.04.03910.1016/j.jconrel.2017.04.039 ↗
36. 10.1056/NEJMra091227310.1056/NEJMra0912273 ↗
37. 10.1016/j.biomaterials.2015.08.04810.1016/j.biomaterials.2015.08.048 ↗
38. 10.1007/s11095-007-9383-410.1007/s11095-007-9383-4 ↗
39. 10.1021/am506429810.1021/am5064298 ↗
40. 10.1016/j.carbpol.2016.05.04310.1016/j.carbpol.2016.05.043 ↗
41. 10.2147/IJN.S7518610.2147/IJN.S75186 ↗
42. 10.1016/j.jconrel.2012.10.01310.1016/j.jconrel.2012.10.013 ↗
43. 10.1016/j.addr.2015.01.00210.1016/j.addr.2015.01.002 ↗
44. 10.1111/j.1751-1097.1978.tb06972.x10.1111/j.1751-1097.1978.tb06972.x ↗
45. 10.1016/j.biomaterials.2012.02.01610.1016/j.biomaterials.2012.02.016 ↗
46. 10.1039/c0cc01413c10.1039/c0cc01413c ↗
47. 10.1021/acsami.5b0863710.1021/acsami.5b08637 ↗
48. 10.1016/j.bbamcr.2008.01.02310.1016/j.bbamcr.2008.01.023 ↗
49. 10.1021/nl900031y10.1021/nl900031y ↗
50. 10.1126/science.609324910.1126/science.6093249 ↗